Tecarfarin sodium (ATI-5923 sodium) 是一种新型口服活性非竞争性维生素 K 环氧化物还原酶 (VKOR) 拮抗剂，会损害维生素K依赖性凝血因子 II，VII，IX 和 X 的活化。Tecarfarin sodium 具有抗血栓形成活性，通过降低维生素 K 依赖性凝血因子的水平来减轻动物模型中静脉和动脉血栓的形成。
CAS：1004551-83-0
分子式：C21H13F6NaO5
分子量：482.31
纯度：98%
存储：Store at -20°C

Background:

Tecarfarin sodium (ATI-5923 sodium) is a novel orally active non-competitive vitamin K epoxide reductase (VKOR) antagonist, impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X[1]. Tecarfarin sodium has the antithrombotic activity, attenuates venous and arterial thrombus formation in animal models by reducing the levels of the vitamin K-dependent coagulation factors[2].

[1]. Hobl EL, et al. Tecarfarin: A Novel Vitamin K Antagonist. Thromb Haemost. 2017 Nov;117(11):2009-2011. [2]. Bowersox SS, et al. Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models. Thromb Res. 2010 Nov;126(5):e383-8.